Staphylococcus epidermidis vaccine conjugate - Nabi

Drug Profile

Staphylococcus epidermidis vaccine conjugate - Nabi

Alternative Names: Staphylococcus epidermidis (PS-1) vaccine conjugate

Latest Information Update: 11 Jun 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 11 Jun 2008 Discontinued - Phase-I for Staphylococcal infections in USA (unspecified route)
  • 10 Feb 2006 Nabi Biopharmaceuticals has completed a phase I trial in Staphylococcal infections in USA
  • 27 May 2005 Phase-I clinical trials in Staphylococcal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top